{"id":"stelara-ustekinumab","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Nasopharyngitis"},{"rate":"8–12","effect":"Upper respiratory tract infection"},{"rate":"5–10","effect":"Headache"},{"rate":"3–8","effect":"Fatigue"},{"rate":"5–10","effect":"Injection site reactions"},{"rate":null,"effect":"Increased infection risk"}]},"_chembl":{"chemblId":"CHEMBL1201835","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ustekinumab binds to the p40 subunit shared by IL-12 and IL-23, preventing these interleukins from activating T cells and other immune cells that drive inflammation. By inhibiting these pathways, it reduces pathogenic Th1 and Th17 cell differentiation and proliferation, thereby suppressing the inflammatory cascade underlying autoimmune and inflammatory diseases.","oneSentence":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of inflammatory and autoimmune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:26.667Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":95},{"nctId":"NCT07487480","phase":"","title":"A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-02-10","conditions":"Inflamatory Bowel Disease, Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":60},{"nctId":"NCT05092269","phase":"PHASE3","title":"A Long-term Extension Study of Ustekinumab in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-18","conditions":"Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic","enrollment":159},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":"Crohn Disease","enrollment":78},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT07449234","phase":"","title":"A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis","status":"RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2026-02-09","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT05083182","phase":"PHASE3","title":"A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-30","conditions":"Arthritis, Juvenile","enrollment":50},{"nctId":"NCT03218488","phase":"","title":"A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen-Cilag International NV","startDate":"2017-10-25","conditions":"Psoriasis","enrollment":135},{"nctId":"NCT06934226","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-04-15","conditions":"Plaque Psoriasis","enrollment":752},{"nctId":"NCT06425549","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-06-25","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":168},{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1056},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT03646708","phase":"","title":"Response Assessment in SB CD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-05-09","conditions":"Small Bowel Crohn's Disease","enrollment":112},{"nctId":"NCT07116967","phase":"PHASE3","title":"Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-22","conditions":"Plaque Psoriasis","enrollment":3040},{"nctId":"NCT06807593","phase":"PHASE2","title":"Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-24","conditions":"Cancer","enrollment":10},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT05387031","phase":"","title":"Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Crohn Disease, Stricture; Bowel, Intestinal Stricture","enrollment":239},{"nctId":"NCT06520397","phase":"PHASE4","title":"Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-07-15","conditions":"Crohn Disease","enrollment":214},{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":"Crohn's Disease","enrollment":300},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Ulcerative Colitis","enrollment":4000},{"nctId":"NCT07245394","phase":"","title":"Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)","status":"RECRUITING","sponsor":"TIDHI Innovation Inc.","startDate":"2026-01-29","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":200},{"nctId":"NCT05327790","phase":"PHASE2","title":"LFMT vs Placebo in New Biologic Start for Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-06-03","conditions":"Ulcerative Colitis","enrollment":40},{"nctId":"NCT03370133","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-12-06","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis","enrollment":567},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":"Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm","enrollment":116},{"nctId":"NCT07303686","phase":"PHASE4","title":"De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-08","conditions":"Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":115},{"nctId":"NCT03167437","phase":"PHASE1, PHASE2","title":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-10-30","conditions":"Crohn's Disease","enrollment":35},{"nctId":"NCT07250815","phase":"","title":"A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2025-12-15","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":23900},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":"Crohn's Disease","enrollment":996},{"nctId":"NCT07268534","phase":"PHASE2","title":"Biologics in Folliculitis Decalvans : an Adaptative Trial Research","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Folliculitis Decalvans (FD)","enrollment":120},{"nctId":"NCT07263464","phase":"","title":"The Association Between TNFSF4 Polymorphism and CD","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Polymorphism, Single Nucleotide, Ustekinumab","enrollment":818},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT07244614","phase":"","title":"Ustekinumab in BEhçet's Syndrome STudy","status":"RECRUITING","sponsor":"Groupe français d'étude des Maladies Inflammatoires de loeil","startDate":"2025-09-01","conditions":"Behçet's Syndrome (BS)","enrollment":208},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT04632927","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-21","conditions":"Psoriatic Arthritis","enrollment":119},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT07198113","phase":"","title":"COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-01","conditions":"Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease","enrollment":1100},{"nctId":"NCT05029921","phase":"PHASE4","title":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":"Crohn Disease","enrollment":182},{"nctId":"NCT07177118","phase":"PHASE3","title":"Risankizumab for Fibrostenotic Crohn's Disease Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-20","conditions":"Crohn Disease, Crohn Disease and Ulcerative Colitis","enrollment":260},{"nctId":"NCT05335356","phase":"PHASE3","title":"Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-06-28","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":384},{"nctId":"NCT02648581","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-14","conditions":"Behçet Disease","enrollment":16},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":"Crohn Disease","enrollment":49},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":"Anoperineal Lesions, Crohn's Disease Relapse","enrollment":52},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":"Psoriasis, Psoriasis Arthritis, Biologics","enrollment":50},{"nctId":"NCT07149467","phase":"PHASE3","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-09-10","conditions":"Crohn's Disease Aggravated, Crohn's Disease in Remission","enrollment":454},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT06738277","phase":"PHASE1","title":"This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-09","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":186},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT07100093","phase":"","title":"Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease.","status":"COMPLETED","sponsor":"Hospital Universitario La Paz","startDate":"2021-07-01","conditions":"Ustekinumab Serum Levels in Patients With Crohn´s Disease","enrollment":100},{"nctId":"NCT06788340","phase":"PHASE4","title":"MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-01","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":166},{"nctId":"NCT06488664","phase":"PHASE3","title":"An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AO GENERIUM","startDate":"2023-07-25","conditions":"Plaque Psoriasis","enrollment":422},{"nctId":"NCT07077681","phase":"","title":"Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar","status":"RECRUITING","sponsor":"EG Labo","startDate":"2025-06-02","conditions":"Crohn Disease (CD)","enrollment":246},{"nctId":"NCT04630028","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-17","conditions":"Colitis, Ulcerative","enrollment":112},{"nctId":"NCT07057856","phase":"","title":"An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Crohn's Disease","enrollment":866},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT06082986","phase":"","title":"A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2023-10-09","conditions":"Crohn Disease","enrollment":200},{"nctId":"NCT01081730","phase":"","title":"Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2010-02-09","conditions":"Psoriasis","enrollment":2040},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06997055","phase":"","title":"ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar","status":"RECRUITING","sponsor":"Celltrion HealthCare France","startDate":"2025-03-17","conditions":"Crohn Disease, Plaque Psoriasis","enrollment":225},{"nctId":"NCT06956703","phase":"","title":"NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2022-12-12","conditions":"Gastro-Intestinal Disorder, Crohn Disease, Ulcerative Colitis","enrollment":240},{"nctId":"NCT04967508","phase":"PHASE3","title":"A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2021-07-06","conditions":"Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":503},{"nctId":"NCT04435600","phase":"PHASE3","title":"A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-14","conditions":"Psoriasis","enrollment":139},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":172},{"nctId":"NCT05242458","phase":"","title":"A Study of Ustekinumab Treatment in Children With Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-21","conditions":"Crohn's Disease","enrollment":545},{"nctId":"NCT06954311","phase":"","title":"Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Medical University Innsbruck","startDate":"2025-02-17","conditions":"Ulcerative Colitis (UC), IBD-unclassified (IBD-U)","enrollment":120},{"nctId":"NCT03981744","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-26","conditions":"Polymyositis, Dermatomyositis","enrollment":51},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT03517722","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-16","conditions":"Lupus Erythematosus, Systemic","enrollment":516},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT02407236","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-10","conditions":"Colitis, Ulcerative, Inflammatory Bowel Diseases","enrollment":961},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":"Crohn Disease","enrollment":500},{"nctId":"NCT04963725","phase":"","title":"A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-07-18","conditions":"Ulcerative Colitis","enrollment":137},{"nctId":"NCT03606499","phase":"","title":"Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases","status":"COMPLETED","sponsor":"Janssen Cilag S.A.S.","startDate":"2018-09-26","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":111},{"nctId":"NCT05252533","phase":"PHASE1","title":"A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-24","conditions":"Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile","enrollment":31},{"nctId":"NCT00741793","phase":"","title":"Biologic Treatment Registry Across Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2002-02-12","conditions":"Arthritis, Rheumatoid, Spondyloarthritis, Axial, Arthritis, Psoriatic","enrollment":2821},{"nctId":"NCT03942120","phase":"","title":"Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2019-04-08","conditions":"Crohn Disease","enrollment":685},{"nctId":"NCT04816513","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":"Healthy","enrollment":300},{"nctId":"NCT02968108","phase":"PHASE1","title":"A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-18","conditions":"Crohn Disease","enrollment":45},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT03465696","phase":"NA","title":"A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-14","conditions":"Psoriasis","enrollment":180},{"nctId":"NCT06935942","phase":"","title":"The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":906},{"nctId":"NCT06935929","phase":"","title":"A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":839},{"nctId":"NCT06912815","phase":"NA","title":"Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.","status":"RECRUITING","sponsor":"Xiang Gao","startDate":"2024-08-01","conditions":"Crohn Disease (CD)","enrollment":184},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT04305327","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2022-12-07","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT05270733","phase":"PHASE4","title":"Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-11-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT04533737","phase":"PHASE4","title":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2020-12-17","conditions":"Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis","enrollment":113},{"nctId":"NCT05896943","phase":"","title":"The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab","status":"COMPLETED","sponsor":"Evangelismos Hospital","startDate":"2022-04-01","conditions":"Ulcerative Colitis","enrollment":38},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT06849739","phase":"","title":"Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-03-02","conditions":"Inflammatory Bowel Diseases","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4038,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Stelara (ustekinumab)","genericName":"Stelara (ustekinumab)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stelara (ustekinumab) is a monoclonal antibody that inhibits interleukin-12, a protein involved in the immune system. It is used to treat conditions such as Crohn's disease, ulcerative colitis, psoriatic arthritis, and systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}